Photodynamic effect of protoporphyrin diarginate (PPArg2) on methicillin-resistant Staphylococcus aureus and human

Mariusz Grinholc1, Anna Kawiak, Julianna Kurlenda

  • 1Department of Biotechnology, Division of Molecular Diagnostics, University of Gdansk and Medical University of Gdansk, Gdańsk, Poland. grinholc@biotech.ug.gda.pl

Acta Biochimica Polonica
|January 25, 2008
PubMed

Insights

Photodynamic inactivation (PDI) using protoporphyrin diarginate shows promise against antibiotic-resistant bacteria. This novel treatment effectively killed methicillin-resistant Staphylococcus aureus while sparing human skin cells.

Area of Science:

  • Antimicrobial research
  • Photodynamic therapy
  • Bacteriology

Background:

  • Rising antibiotic resistance necessitates novel antimicrobial strategies.
  • Photodynamic inactivation (PDI) presents a potential alternative treatment.
  • Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant public health threat.

Purpose of the Study:

  • To evaluate the phototoxicity of protoporphyrin diarginate (PPArg(2)) against MRSA.
  • To assess the safety of PPArg(2)-mediated PDI on human dermal fibroblasts.

Main Methods:

  • Methylthiazole tetrazolium (MTT) assay was used for cell viability assessment.
  • PPArg(2) concentrations ranging from 0 to 20 microM were tested.
  • A light dose of 6 J cm(-2) was applied during experiments.

Main Results:

  • PPArg(2) at 10 microM with light reduced MRSA viable count by 3.6 log(10) units.
  • Under identical conditions, only 22.5% of human dermal fibroblasts were photoinactivated.
  • PPArg(2) showed no inherent toxicity to either bacteria or fibroblasts without irradiation.

Conclusions:

  • PPArg(2)-mediated PDI demonstrates significant bactericidal efficacy against MRSA.
  • The treatment exhibits a favorable safety profile, with minimal impact on human dermal fibroblasts.
  • PPArg(2) represents a promising therapeutic agent for combating antibiotic-resistant bacterial infections.

Related Concept Videos

Staphylococcal Skin Infections01:29

Staphylococcal Skin Infections

Staphylococcus aureus is a Gram-positive coccus that resides harmlessly on the skin and mucous membranes of healthy individuals. When the skin barrier is breached, it can shift from a commensal to an opportunistic pathogen. This transition is facilitated by surface adhesins, such as clumping factor B and S. aureus surface protein G (SasG), which bind to structural proteins, including loricrin and cytokeratin, in the damaged epidermis. Protein A, another key factor, binds the Fc region of...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...